Related Experiment Video
Updated: Oct 16, 2025
06:15
Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
Published on: November 10, 2023
1.1K
Blocking hyaluronan synthesis alleviates acute lung allograft rejection
Jewel Imani1, Kaifeng Liu2, Ye Cui1
1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JCI Insight
|October 19, 2021
Summary
4-Methylumbelliferone (4MU) reduces lung allograft rejection by inhibiting hyaluronic acid (HA) synthesis. This treatment improved transplant outcomes, reduced inflammation, and showed potential for clinical use in lung transplantation.
Area of Science:
- Immunology
- Transplantation Biology
- Pharmacology
Background:
- Lung allograft rejection involves hyaluronic acid (HA) accumulation, worsening inflammation and injury.
- Therapeutic lymphangiogenesis previously reduced HA and improved lung transplant outcomes in murine models.
Purpose of the Study:
- To investigate 4-Methylumbelliferone (4MU), a hyaluronic acid synthesis inhibitor, for treating acute lung allograft rejection.
- To assess 4MU's efficacy in a murine lung transplantation model.
Main Methods:
- Mice with lung allografts were treated with 4MU between days 20 and 30 post-transplant.
- Evaluated T cell-mediated inflammation, low-molecular weight hyaluronic acid (LMW-HA) content, and pathology scores.
- In vitro studies assessed 4MU's effect on naive CD4+ T cell activation, proliferation, and Th1 differentiation.
Main Results:
- 4MU treatment significantly improved lung allograft transplant outcomes.
- Reduced T cell-mediated lung inflammation and decreased LMW-HA content were observed.
- 4MU attenuated naive CD4+ T cell activation, proliferation, and Th1 differentiation in vitro.
Conclusions:
- 4MU effectively alleviates acute lung allograft rejection in a murine model.
- The drug reduces inflammation and LMW-HA accumulation, improving transplant outcomes.
- Given its established human safety, 4MU warrants clinical investigation for treating lung allograft rejection.
